JAKARTA. PT Phapros Tbk (PEHA), a pharmaceutical company under PT Kimia Farma Tbk (KAEF), seeks double-digit growth in 2023 through the launch of new products.

Hadi Kardoko, President Director of PEHA, claimed that the new product will be introduced so that the company will be able to face the vigorous competition in the pharmaceutical sector. The innovation strategy and the company’s new product launch have been initiated since last year.

“Throughout 2022, we have launched 13 products alongside our subsidiary, PT Lucas Djaja Group,” Kardoko told IDNFinancials earlier today. “These 13 products originate from the development and research, which have been adjusted to the public’s needs,” he said.

This year, Kardoko said that PEHA has prepared 10 to 12 new products in order to boost the company’s performance so that it could attain the predetermined target. Some of these new products are categorized as therapeutic products. “Some of them include antibiotics, multivitamins, and other products for therapy, which are included in the first-line therapy,” he explained.

In order to support product innovation, PEHA has formed partnerships with several institutions, including Airlangga University and dr. Soetomo Regional Hospital in Surabaya. This collaboration is said to reinforce the research downstreaming initiated by the company. (KR/ZH)